Pharma Executives To Watch In China In 2017
From general managers of multinationals to new CEOs of domestic innovative startups, a string of recently minted executives will help shape the future of the pharma industry in China.
You may also be interested in...
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.